Drug Discovery World

JANUARY 25, 2024

Japan-based pharma company Kyowa Kirin has successfully completed the acquisition of gene therapy developer Orchard Therapeutics. Libmeldy is approved by the European Commission (EC) and UK Medicines and Healthcare products Regulatory Agency (MHRA).

Gene Therapy 52

Gene Therapy Gene Pharma Companies Drugs 52

XTalks

MARCH 28, 2024

Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein. Bettica said the company’s focus is to now “make Duvyzat available as a treatment for DMD management in the US as quickly as possible.” The drug generated domestic sales of $200.4

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

XTalks

OCTOBER 4, 2023

Heather McDonald: My previous role at Bayer was a global-level role with a specific focus on cell and gene therapies. In addition, AstraZeneca just announced a major acquisition of Pfizer’s cell and gene therapy portfolio. You almost can’t start early enough when looking at how to optimize patient access for innovative medicines.

Marketing 105

Marketing Development Drugs Gene Therapy 105

BioTech 365

OCTOBER 15, 2020

ISTANBUL–(BUSINESS WIRE)– Company name: Er-Kim Ilac Presentative: Cem Zorlular, CEO AnGes, Inc.,

Pharma Companies 40

Pharma Companies Licensing Licensing Gene 40

pharmaphorum

DECEMBER 29, 2022

At the same time, the industry must address the long-term difficulty of providing essential medicines and health services to the high percentage of global population that cannot access them because of costs. Ensuring on-time delivery of life-saving medicine. Crisis readiness and digital workflows.

Manufacturing 103

Manufacturing Medicine Pharma Companies Engineer 103

pharmaphorum

SEPTEMBER 3, 2020

King’s Cross is also home to Google’s DeepMind artificial intelligence company, which has already been involved in life sciences projects such as using the technology to predict acute kidney injury. She added: “Using technologies like AI is a critical part of helping us to discover and develop medicines for serious diseases.”.

Life Science 103

Life Science Engineer Scientist Pharma Companies 103

Drug Discovery World

AUGUST 4, 2023

With so many exciting novel treatments emerging from the labs, biotechs and pharma companies need to understand the potential unknowns as well as the known considerations if they are to optimise their impact in the real world. Other challenges involve talent gaps, particularly now that cell and gene therapy manufacturing is maturing.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

XTalks

DECEMBER 29, 2022

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. 1. Cell and Gene Therapies. Here are four life sciences trends to look out for in 2023.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

JANUARY 24, 2023

Pharma has used this to begin creating targeted treatments, such as gene therapies , which are able to hone in on gene mutations that cause health issues and eradicate or replace the faulty gene. Certain genetic variants influence the way the body responds to specific medicine.

Genetics 90

Genetics Drugs Genome Project Biobanking 90

Pharmaceutical Technology

JANUARY 31, 2023

While insulin price caps will begin this year, larger effects will be delayed until 2026 – when the US federal government will be allowed to negotiate Medicare prices and demand rebates from drug companies that price gouge. That leaves three years for pharma companies to prepare. It’s much needed. It’s a hot area.”

Drugs 130

Drugs Regulation Gene Therapy Insulin 130

pharmaphorum

NOVEMBER 23, 2021

The DISC is the biggest investment AZ has ever made, and has been hailed by the pharma company’s chief executive Pascal Soriot as the centrepiece of what he believes could one day become a biotech hub to rival Boston and San Francisco in the US.

Gene Editing 105

Gene Editing Life Science Pharma Companies Clinical Trials 105

pharmaphorum

NOVEMBER 30, 2022

The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine? The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas.

Life Science 95

Life Science Pharma Companies Sales Marketing 95

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

NOVEMBER 16, 2020

EMA executive director Guido Rasi has ended his second term at the helm of the EU medicines regulator, with Emer Cooke taking the wheel and becoming the first women in the role. Cooke is returning to the EMA after a four-year period as head of medicines regulation at the World Health Organization (WHO). Emer Cooke.

Regulation 64

Regulation Medicine Vaccination Vaccine 64

Drug Discovery World

APRIL 3, 2023

As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

pharmaphorum

NOVEMBER 22, 2022

Francis, who is currently CEO of gene therapy specialist Purespring Therapeutics and cardiovascular drug developer company Forcefield Therapeutics, is due to take the top job at Teva on 1 January, and will serve as the pharma company’s president. Richard Francis.

Sales 59

Sales Gene Therapy Pharma Companies Gene 59

Drug Discovery World

OCTOBER 16, 2023

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. billion in funding. Government investment of £1.3

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. There are a growing number of biotech and pharma companies that have established or are establishing such end-to-end cell therapy capabilities, which can also play into how collaborations are structured in the field.

Research 122

Research Gene Editing Gene Development 122

Drug Discovery World

FEBRUARY 6, 2024

Companies leading the way There are a number of companies leading the charge in applying innovative technologies, particularly artificial intelligence (AI) and machine learning (ML), to the search for new medicines.

Marketing 69

Marketing Medicine Genome Genomics 69

Drug Discovery World

DECEMBER 27, 2023

In this episode, Kelland shares what she means by the ‘next pandemic’, the lessons learnt from the Covid-19 pandemic, and the role of global health organisations and pharma companies going forward. Dr Pace discusses how precision medicine is already starting to influence standards in clinical trial design. Listen here.

Clinical Trials 69

Clinical Trials Clinical Trials Drugs Development 69

Drug Discovery World

MARCH 29, 2023

An example of the current disparity, drawn from data from the European Federation of Pharmaceutical Industries and Associations (EFPIA), can be seen in Romania, Poland or Bulgaria, where a recently approved medicine will take more than 800 days on average before it becomes publicly available compared with Germany, where that figure is 133 days 3.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

Drug Discovery World

SEPTEMBER 28, 2022

Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. NEC, the Japanese IT and electronics corporation, has pivoted towards drug discovery with a focus on personalised medicines.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

Drug Discovery World

DECEMBER 14, 2023

The new centre represents a flagship investment within the University’s Glasgow Riverside Innovation District (GRID) and will be home to commercial businesses as well as the University of Glasgow-led Living Laboratory for Precision Medicine. This is a core competency of BioAscent and we are enthusiastic in collaborating with the universities.”

Drugs 75

Drugs Life Science Research Scientist 75

pharmaphorum

APRIL 28, 2022

Despite the inherent difficulties, major pharma companies do take aim at rare diseases, usually with dedicated units focusing on clusters of rare diseases that afflict the same part of the body. How big pharma tackles rare diseases. It’s a different business model, if you will,” Miquel said. “So So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

XTalks

OCTOBER 22, 2020

In this sense, pharmaceutical companies have developed different strategies to produce a wide variety of advanced therapy medicinal products (ATMP) and biological products, such as monoclonal antibodies, recombinant proteins, gene therapy viral vectors, CAR-T cells and oncolytic viruses, in order to deliver new medical needs in our society.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

XTalks

DECEMBER 20, 2023

Check out this article to learn about the biotech companies that went public this year. The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

pharmaphorum

JUNE 11, 2021

Ocugen is the first company to be affected by the FDA’s recent decision to raise the bar on emergency use authorisations for COVID-19 medicines, and will have to file for full approval of its vaccine candidate.

Vaccination 61

Vaccination Vaccine Clinical Trials Clinical Trials 61

Delveinsight

DECEMBER 15, 2020

Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development in the NASH landscape and help its commercialization in the market.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

Drug Discovery World

FEBRUARY 10, 2023

More so, the Karolinska Institute is ranked at number seven in the world for the subjects of life sciences and medicine. Swedish life sciences industry organisation Lif put the success down to the government’s continued investment in life sciences and the increase in international companies investing in Sweden’s manufacturing sector.

Life Science 52

Life Science Drugs Gene Therapy Manufacturing 52

pharmaphorum

NOVEMBER 23, 2022

We looked at the areas of rare diseases, cell and gene therapy, vaccines – loads of different perspectives. Materials to market, medicines to patients. In terms of the impact on patient engagement, such a process brings required medicines to market, and to the right patients, much faster.

Life Science 98

Life Science Marketing Medicine Production 98

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. But there was some considerable progress in other fields of medicine even though research efforts were diverted away, reports Richard Staines. Rare disease progress.

Marketing 77

Marketing Gene Silencing Gene Drugs 77

Pharmaceutical Technology

MAY 24, 2023

By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.

Clinical Trials 246

Clinical Trials Clinical Trials Gene Therapy Clinical Supply Chain 246

Camargo

MARCH 9, 2021

The FDA revealed that pharma companies are not forthcoming when they publicly disclose the reasons behind a refuse-to-file (RTF) letter from the Agency. In fact, when they do disclose their existence, companies disclosed only 5% of the reasons for the RTF.

Development 146

Development Manufacturing Drugs Production 146

pharmaphorum

NOVEMBER 12, 2020

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Pharmaceutical Technology

JUNE 14, 2023

Future waves of approvals for ATMPs (advanced therapy medicinal products, e.g., cell and gene therapies) will heighten demand on the contract packaging industry, further increasing the need for advanced cold chain solutions and specialized packaging designed to withstand cryogenic temperatures.

Contract Packaging 130

Contract Packaging Packaging Packaging Development 130

XTalks

DECEMBER 20, 2023

In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

XTalks

MAY 11, 2023

I know you also serve on the board of directors for Global Genes, which recently merged with RARE-X. Wendy: RARE-X is now the data and research arm of Global Genes, the flagship patient organization representing rare, ultra-rare, and “n-of-one” patients. And the idea of personalized medicine was starting to take off.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97